🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,121 results for “ACE” Clear

  1. Adynovate

    Takeda Pharmaceuticals International AG

    Hemophilia A

    phase 3 mab completed

    1 trial

  2. Aficamten, Tablet placebo for aficamten 5mg tablet

    Cytokinetics (Ireland) Limited

    SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY

    phase 3 small molecule active

    1 trial

  3. Afinitor 10 mg tablets, Aromasin 25 mg coated tablets, Faslodex 250 mg solution for injection., Afinitor 5 mg tablets

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Hormone receptor-positive, her2-negative advanced/metastatic breast cancer

    phase 3 small molecule active

    1 trial

  4. Afinitor 5 mg tablets, PLACEBO

    Cancer Prevention Pharma (Ireland) Limited

    Patients with high risk of relapse, ER+ and HER2- primary non-metastatic breast cancer who remain disease-free

    phase 3 small molecule active

    1 trial

  5. Alicaforsen

    IONIS PHARMACEUTICALS INC

    Crohn's Disease

    phase 3 small molecule completed

    2 trials

  6. Alisertib

    Takeda Pharmaceuticals International AG

    Relapsed Peripheral T-Cell Lymphoma

    phase 3 small molecule completed

    1 trial

  7. Almonertinib

    China SXT Pharmaceuticals

    Non-small Cell Lung Cancer Metastatic

    phase 3 small molecule active

    1 trial

  8. Alogliptin

    Takeda Pharmaceuticals International AG

    Diabetes Mellitus

    phase 3 small molecule completed

    9 trials

  9. Alogliptin Benzoate

    Takeda Pharmaceuticals International AG

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  10. Alogliptin and glimepiride

    Takeda Pharmaceuticals International AG

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  11. Alogliptin and glyburide

    Takeda Pharmaceuticals International AG

    Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  12. Alogliptin and insulin

    Takeda Pharmaceuticals International AG

    Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  13. Alogliptin and metformin

    Takeda Pharmaceuticals International AG

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  14. Alogliptin and metformin

    Takeda Pharmaceuticals International AG

    Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  15. Alogliptin and pioglitazone

    Takeda Pharmaceuticals International AG

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  16. Alogliptin and pioglitazone

    Takeda Pharmaceuticals International AG

    Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  17. Alogliptin and voglibose

    Takeda Pharmaceuticals International AG

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  18. Alyftrek 125 mg/50 mg/10 mg film-coated tablets, VX-121/VX-661/VX-561 Film-coated tablet

    Vertex Pharmaceuticals (Ireland) Limited

    Cystic Fibrosis

    phase 3 small molecule active

    1 trial

  19. Ambrisentan Viatris 5 mg film-coated tablets, Placebo de AMBRISENTAN VIATRIS 5 mg - composition: cellulose microcristalline; lactose monohydraté; silice colloïdale anhydre; stéarate de magnésium (vegetable origin); opadry II 85G94065 PINK; eau purifiée, TADALAFIL

    Pari Pharma GmbH

    Pulmonary arterial hypertension

    phase 3 small molecule active

    1 trial

  20. Amifampridine Phosphate

    CATALYST PHARMACEUTICALS, INC.

    Myasthenia Gravis, Generalized

    phase 3 small molecule completed

    1 trial

  21. Amifampridine Phosphate

    CATALYST PHARMACEUTICALS, INC.

    Lambert Eaton Myasthenic Syndrome

    phase 3 small molecule completed

    2 trials

  22. Amifampridine Phosphate

    CATALYST PHARMACEUTICALS, INC.

    Myasthenia Gravis, MuSK

    phase 3 small molecule terminated

    1 trial

  23. Amlitelimab, Placebo, -, TACROLIMUS , PIMECROLIMUS , Amlitelimab

    Sanofi Pharma Bristol-Myers Squibb

    Dermatitis atopic

    phase 3 small molecule active

    1 trial

  24. Amlitelimab, Placebo, Amlitelimab, PIMECROLIMUS , -, TACROLIMUS

    Sanofi Pharma Bristol-Myers Squibb

    atopic dermatitis

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources